NCT06695845 2026-02-25A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsJazz PharmaceuticalsPhase 2 Recruiting200 enrolled
NCT03929666 2025-09-12A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerJazz PharmaceuticalsPhase 2 Completed74 enrolled